GIMV NV 4
4 · MEMORY PHARMACEUTICALS CORP · Filed Apr 12, 2004
Insider Transaction Report
Form 4
GIMV NV
Other
Transactions
- Conversion
Common Stock
2004-04-08+166,408→ 166,408 total - Conversion
Series C Convertible Preferred Stock
2004-04-08−200,000→ 0 total→ Common Stock (71,170 underlying) - Conversion
Series D Convertible Preferred Stock
2004-04-08−1,395,349→ 0 total(indirect: See Footnote)→ Common Stock (465,116 underlying) - Conversion
Series B Convertible Preferred Stock
2004-04-08−285,714→ 0 total→ Common Stock (95,238 underlying) - Conversion
Common Stock
2004-04-08+465,116→ 465,116 total(indirect: See Footnote)
Footnotes (5)
- [F1]The shares of Series D Convertible Preferred Stock reported consist of shares held of record by each of the entities listed below. GIMV and Adviesbeheer GIMV Life Sciences each owned 1,186,047 and 209,302 shares of Series D Convertible Preferred Stock respectively. Upon conversion, GIMV and Adviesbeheer GIMV Life Sciences each own 395,349 and 69,767 shares of common stock respectively. Each of the Filing Persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
- [F2]Each share of Convertible Preferred Stock converted into .3333 shares of Common Stock.
- [F3]These securities automatically converted into Common Stock upon the closing of the Issuer's intitial public offering.
- [F4]These securities do not have an expiration date.
- [F5]Each share of Convertible Preferred Stock converted into .3559 shares of Common Stock.